<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17563841</article-id><article-id pub-id-type="pmc">3476139</article-id><article-id pub-id-type="publisher-id">386</article-id><article-id pub-id-type="doi">10.1007/s10194-007-0386-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Rizatriptan <italic>vs.</italic> ibuprofen in migraine: a randomised placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Misra</surname><given-names>Usha Kant</given-names></name><address><phone>+91-0522-2668004-8 ext. 2167</phone><fax>+91-0522-2668017</fax><email>ukmisra@sgpgi.ac.in</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kalita</surname><given-names>Jayantee</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Rama Kant</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareily Road, Lucknow, 226014 India </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>6</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><volume>8</volume><issue>3</issue><fpage>175</fpage><lpage>179</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag Italia 2007</copyright-statement></permissions><abstract id="Abs1"><p>The objective of this study was to compare the efficacy of rizatriptan and ibuprofen in migraine. The study was a randomised placebo-controlled trial in a tertiary care teaching hospital. Migraine patients with &#x0003c;8 attacks/months were included. One hundred and fifty-five migraine patients were randomised to rizatriptan 10 mg (53), ibuprofen 400 mg (52) and placebo (50). Efficacy was assessed by headache relief, and headache freedom at 2 h and 24 h. Two-hour headache relief, was noted in 73% in rizatriptan, 53.8% in ibuprofen and 8% in placebo groups. Headache freedom was achieved in 37.7% in rizatriptan, 30.8% in ibuprofen and 2% in placebo groups. Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h. Side effects were noted in 9 patients in rizatriptan, 8 in ibuprofen and 3 in placebo, all of which were nonsignificant. Rizatriptan and ibuprofen are superior to placebo. Rizatriptan is superior to ibuprofen in relieving headache, associated symptoms and functional disability.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Migraine</kwd><kwd>Rizatriptan</kwd><kwd>Acute attack</kwd><kwd>Randomised controlled trial</kwd><kwd>Treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Italia 2007</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>U.K.</given-names></name><name><surname>Jose</surname><given-names>M.</given-names></name><name><surname>Kalita</surname><given-names>J.</given-names></name></person-group><article-title>Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial</article-title><source>Postgrad Med J</source><year>2004</year><volume>80</volume><fpage>720</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1136/pgmj.2003.012393</pub-id><pub-id pub-id-type="pmid">15579612</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S.D.</given-names></name></person-group><article-title>Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>754</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">10993991</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>J.L.</given-names></name><name><surname>Fernandez-Alonso</surname><given-names>J.</given-names></name></person-group><article-title>Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1946</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)05083-2</pub-id><pub-id pub-id-type="pmid">11425419</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamalainen</surname><given-names>M.L.</given-names></name><name><surname>Hoppu</surname><given-names>K.</given-names></name><name><surname>Valkeila</surname><given-names>E.</given-names></name><name><surname>Santavuori</surname><given-names>P.</given-names></name></person-group><article-title>Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study</article-title><source>Neurology</source><year>1997</year><volume>48</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">9008503</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havaka-Kanniainen</surname><given-names>H.</given-names></name></person-group><article-title>Treatment of acute migraine attack: ibuprofen and placebo compared</article-title><source>Headache</source><year>1989</year><volume>29</volume><fpage>507</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1989.hed2908507.x</pub-id><pub-id pub-id-type="pmid">2676908</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caklwell</surname><given-names>J.</given-names></name><name><surname>Holt</surname><given-names>P.</given-names></name></person-group><article-title>MK 0966, a specific COX 2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week control trial</article-title><source>Arthritis Rheum</source><year>1998</year><volume>41</volume><fpage>S83</fpage></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codispoti</surname><given-names>J.R.</given-names></name><name><surname>Prior</surname><given-names>M.J.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy of nonprescription doses of ibuprofen for treating migraine headache: a randomized controlled trial</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>665</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2001.041007665.x</pub-id><pub-id pub-id-type="pmid">11554954</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adelman</surname><given-names>J.U.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Ferrari</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>Comparison of rizatriptan and other triptans on stringent measures of efficacy</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>1377</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">11673575</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christie</surname><given-names>S.</given-names></name><name><surname>Gobel</surname><given-names>H.</given-names></name><name><surname>Mateos</surname><given-names>V.</given-names></name><collab>Rizatriptan-Ergotamine/Caffeine Preference Study Group</collab><etal/></person-group><article-title>Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine</article-title><source>Eur Neurol</source><year>2003</year><volume>49</volume><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1159/000067018</pub-id><pub-id pub-id-type="pmid">12464714</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society.</collab></person-group><article-title>Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain</article-title><source>Cephalalgia</source><year>1988</year><volume>7</volume><issue>[Suppl7]</issue><fpage>1</fpage><lpage>96</lpage></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>M.S.</given-names></name><name><surname>Matzura-Wolfe</surname><given-names>D.</given-names></name><name><surname>Polis</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">9748025</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolster</surname><given-names>R.</given-names></name><name><surname>Nestvold</surname><given-names>K.</given-names></name><name><surname>Vilming</surname><given-names>S.T.</given-names></name></person-group><article-title>A double blind study of ibuprofen versus placebo in the treatment of acute migraine attacks</article-title><source>Cephalalgia</source><year>1992</year><volume>12</volume><fpage>169</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1992.1203169.x</pub-id><pub-id pub-id-type="pmid">1623513</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellstein</surname><given-names>D.E.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Geetha</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized double blind, placebo-controlled, dose ranging study</article-title><source>Cephalalgia</source><year>2000</year><volume>20</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00055.x</pub-id><pub-id pub-id-type="pmid">10999673</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>H.C.</given-names></name><name><surname>Bussone</surname><given-names>G.</given-names></name><name><surname>Liano</surname><given-names>H.</given-names></name><etal/></person-group><article-title>EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><fpage>947</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00783.x</pub-id><pub-id pub-id-type="pmid">15482357</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>T.R.</given-names></name><name><surname>Sunshine</surname><given-names>A.</given-names></name><name><surname>Stark</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Sumatriptan and naproxen sodium for the acute treatment of migraine</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>983</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05178.x</pub-id><pub-id pub-id-type="pmid">16109111</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraud</surname><given-names>G.</given-names></name><name><surname>Compagnon</surname><given-names>A.</given-names></name><name><surname>Rossi</surname><given-names>A.</given-names></name><collab>COZAM Study Group</collab></person-group><article-title>Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study</article-title><source>Eur Neurol</source><year>2002</year><volume>47</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1159/000047959</pub-id><pub-id pub-id-type="pmid">11844897</pub-id></mixed-citation></ref></ref-list></back></article>